openPR Logo
Press release

Alpha-1 Antitrypsin Deficiency Treatment Market Size 2025-2033

09-08-2025 12:26 PM CET | Health & Medicine

Press release from: IMARC Group

Alpha-1 Antitrypsin Deficiency Treatment Market Size

The alpha-1 antitrypsin deficiency market is witnessing significant growth, driven by increasing awareness and advancements in diagnostic techniques. AATD is a genetic disorder characterized by low levels or malfunctioning of the alpha-1 antitrypsin protein, leading to heightened risks of lung and liver diseases. In 2023, the market across seven major regions was valued at USD 1.4 million. Projections indicate a robust growth trajectory, with expectations to reach USD 3.9 million by 2034, reflecting a compound annual growth rate (CAGR) of 9.83% during the forecast period.

Request for a sample copy of this report:
https://www.imarcgroup.com/alpha-1-antitrypsin-deficiency-market/requestsample

Study Assumption Years

• Base Year: 2023
• Historical Years: 2018-2023
• Forecast Years: 2024-2034

Alpha-1 Antitrypsin Deficiency Market Key Takeaways

• Market Size & Growth: The AATD market was valued at USD 1.4 million in 2023 and is projected to reach USD 3.9 million by 2034, growing at a CAGR of 9.83%.
• Regional Dominance: The United States holds the largest patient pool and represents the most significant market for AATD treatment.
• Therapeutic Advancements: Augmentation therapy, involving regular intravenous infusions of purified alpha-1 antitrypsin protein, is widely adopted to protect lungs from protease enzyme imbalance.
• Diagnostic Improvements: Enhanced diagnostic methods, including genetic testing for SERPINA1 gene mutations, are facilitating early and accurate detection of AATD.
• Research & Development: Key players are investing in R&D to develop disease-modifying therapies aimed at reducing misfolded protein accumulation and enhancing clearance of abnormal protein aggregates.
• Genetic Testing Expansion: The use of expanded genetic panels is gaining popularity, allowing identification of rare or novel mutations, thereby improving diagnostic accuracy.
• Pulmonary Rehabilitation: Increasing utilization of pulmonary rehabilitation programs is aiding in improving lung function and overall respiratory health among AATD patients.

Market Growth Factors

1. Alpha-1 antitrypsin deficiency treatment market growth

The Alpha-1 Antitrypsin Deficiency (AATD) treatment market is experiencing significant growth, driven by a combination of factors. A key driver is the increasing awareness and diagnosis rates of the disease, which is often underdiagnosed. Enhanced screening programs, including those for newborns and individuals with COPD, are leading to earlier and more frequent identification of AATD patients.

2. Rising demand for COPD and emphysema therapies in AATD patients

The treatment landscape for Alpha-1 antitrypsin deficiency (AATD) is increasingly focused on managing its most common and devastating manifestation: lung disease, specifically COPD and emphysema. As awareness of AATD grows and diagnostic methods improve, there's a rising demand for therapies that can effectively slow the progression of lung damage. The cornerstone of AATD-specific treatment is augmentation therapy, which involves weekly or biweekly infusions of a human plasma-derived protein. This treatment aims to raise the protective level of the alpha-1 antitrypsin protein in the lungs, thereby inhibiting the elastase enzyme that causes tissue destruction.

3. Growing demand for liver disease management in AATD patients

The management of liver disease in patients with Alpha-1 Antitrypsin Deficiency (AATD) is a growing concern, driven by increasing awareness and a better understanding of the condition's dual impact on both the lungs and liver. While augmentation therapy exists for lung-related AATD, there is currently no specific treatment to prevent the accumulation of the misfolded protein that causes liver damage. This has led to a rising demand for comprehensive care focused on monitoring, symptom management, and risk reduction.

Request for a sample copy of this report:
https://www.imarcgroup.com/alpha-1-antitrypsin-deficiency-market/requestsample

Market Segmentation

Breakup by Region:

o North America (United States, Canada)
o Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
o Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
o Latin America (Brazil, Mexico, Others)
o Middle East and Africa

Regional Insights

The United States really stands out as the top market for treating alpha-1 antitrypsin deficiency, thanks to its large patient base and cutting-edge healthcare system. The focus on early diagnosis, the widespread use of augmentation therapy, and significant investments in research and development are all driving the growth of this market. Plus, with major pharmaceutical companies in the mix and supportive reimbursement policies, the U.S. is solidifying its strong position in the global AATD scene.

Recent Developments & News

The alpha-1 antitrypsin deficiency market is buzzing with recent advancements, particularly thanks to significant investments in research and development aimed at bringing disease-modifying therapies to life. These therapies are all about reducing the buildup of misfolded alpha-1 antitrypsin protein in cells and improving the clearance of those pesky abnormal protein aggregates. Plus, the growing trend of using expanded genetic panels is exciting, as they help identify rare or novel mutations, which in turn enhances the accuracy of genetic diagnoses. All these developments are fostering a hopeful outlook for the market, signalling a move towards more personalized and effective treatment options for AATD patients.

Key Players

Grifols, Kamada, CSL Behring, Arrowhead Pharmaceuticals, Takeda Pharmaceuticals USA, Inhibrx, Vertex Pharmaceuticals, Dicerna Pharmaceuticals.

Ask Analyst for Customization:
https://www.imarcgroup.com/request?type=report&id=7844&flag=C

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as part of the customization.

Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: (+1-201971-6302)

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include a thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape, and benchmarking analyses, pricing and cost research, and procurement research.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Alpha-1 Antitrypsin Deficiency Treatment Market Size 2025-2033 here

News-ID: 4173635 • Views:

More Releases from IMARC Group

Private Equity Market is Expected to Grow USD 1,670.43 Billion by 2033 | At CAGR 8.73%
Private Equity Market is Expected to Grow USD 1,670.43 Billion by 2033 | At CAGR …
Overview Private Equity Market Outlook: The private equity market plays a crucial role in the global financial ecosystem, providing capital to privately held companies or acquiring public companies to restructure them for long-term value creation. Unlike public markets, private equity investments are typically illiquid and made by institutional investors, high-net-worth individuals, and private equity (PE) firms seeking higher returns. The market's growth is driven by increasing corporate restructuring activities, demand for
Technical Textiles Business Plan 2025: Setup Costs, Revenue & Profitability
Technical Textiles Business Plan 2025: Setup Costs, Revenue & Profitability
Overview: IMARC Group's "Technical textiles Business Plan and Project Report 2025" offers a comprehensive framework for establishing a successful Technical textiles business. This in-depth report covers critical aspects such as market trends, investment opportunities, revenue models, and financial forecasts, making it an essential tool for entrepreneurs, consultants, and investors. Whether assessing a new venture's feasibility or optimizing an existing business, the report provides a deep dive into all components necessary for
Setting Up GaN Power Devices Plant in Saudi Arabia: A Comprehensive Guide for Entrepreneurs
Setting Up GaN Power Devices Plant in Saudi Arabia: A Comprehensive Guide for En …
IMARC Group's "GaN Power Devices Production Cost Analysis Report 2025: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue" provides a detailed roadmap for establishing a GaN power devices manufacturing plant in Saudi Arabia. The report offers every critical aspect of the setup process, such as unit operations, raw material requirements, utility supply, infrastructural needs, machinery models, labour necessities, transportation timelines, packaging costs, etc. In addition to the
Philippines Aquaculture Market 2025 | Expected to Reach 0.59 Million Tons by 2033
Philippines Aquaculture Market 2025 | Expected to Reach 0.59 Million Tons by 203 …
The latest report by IMARC Group, "Philippines Aquaculture Market Size, Share, Trends and Forecast by Fish Type, Environment, Distribution Channel, and Region, 2025-2033," provides an in-depth analysis of the Philippines aquaculture market. The report also includes competitor and regional analysis, along with a breakdown of segments within the industry. The Philippines aquaculture market size reached 0.37 million tons in 2024 and is projected to grow to 0.59 million tons by

All 5 Releases


More Releases for AATD

Alpha-1 Antitrypsin Deficiency (AATD) Market Emerging Trends and Growth Prospect …
Introduction Alpha-1 Antitrypsin Deficiency (AATD) is a rare genetic disorder that can cause progressive lung conditions such as emphysema, chronic obstructive pulmonary disease (COPD), and liver disease including cirrhosis and hepatocellular carcinoma. With growing awareness, advancements in genetic testing, and a rising focus on orphan drug development, the AATD market is entering a transformative phase. By combining established augmentation therapies with innovative approaches such as gene therapy and RNA interference (RNAi) therapeutics,
Alpha-1 Antitrypsin Deficiency (AATD) Market Set to Witness Significant Growth b …
Introduction Alpha-1 Antitrypsin Deficiency (AATD) is a rare genetic disorder caused by mutations in the SERPINA1 gene, leading to low levels or dysfunction of the alpha-1 antitrypsin (AAT) protein. This protein protects tissues from enzyme-related damage, and its deficiency predisposes patients to early-onset emphysema, chronic obstructive pulmonary disease (COPD), liver disease, and, in some cases, skin problems such as panniculitis. Historically, augmentation therapy using plasma-derived AAT has been the standard treatment to
Alpha-1 Antitrypsin Deficiency (AATD) Market New Product Development & Latest Tr …
Introduction Alpha-1 antitrypsin deficiency (AATD) is a rare genetic disorder caused by mutations in the SERPINA1 gene, leading to low levels of the alpha-1 antitrypsin (AAT) protein. This protein normally protects the lungs from neutrophil elastase; deficiency results in early-onset chronic obstructive pulmonary disease (COPD), emphysema, and liver disease. Despite affecting an estimated 1 in 2,500-5,000 people of European descent, AATD is significantly underdiagnosed due to overlapping symptoms with asthma and COPD.
Alpha-1 Antitrypsin Deficiency Pipeline: 40+ Pioneering Companies Driving Innova …
The Alpha-1 antitrypsin deficiency market is entering a new era of innovation, driven by over 20 leading biotech and pharma players, including Intellia Therapeutics, Apic Bio, Linton Pharm, Z Factor Limited, Vertex Pharmaceuticals, Grifols, and Kamada. These visionaries are reshaping treatment paradigms with next-gen therapies that promise greater precision and better outcomes. DelveInsight's "Alpha-1 Antitrypsin Deficiency Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Alpha-1
Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue, Trend …
New York, United States, - The Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market size is estimated to grow at a CAGR of 6.2% between 2023 and 2032. The growth of the market depends on several factors, including the increasing prevalence of Alpha-1 Antitrypsin Deficiency, advancements in treatment options, and rising awareness about this genetic disorder. Alpha-1 Antitrypsin Deficiency is a genetic condition that can lead to lung and liver
Globally, More than 12+ Companies are Developing 12+ Therapies in Alpha1-Antitry …
"Alpha-1 Antitrypsin Deficiency Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Alpha-1 Antitrypsin Deficiency Therapeutics Market. The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the